A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Metastatic Non-Small Cell Lung Cancer
- Determine the partial and complete objective response rate in patients with metastatic
non-small cell lung cancer treated with 3-AP and gemcitabine.
- Determine the progression-free and overall survival in patients treated with this
- Determine the safety of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive 3-AP IV over 4 hours followed by gemcitabine IV over 30 minutes once weekly
on weeks 1-3. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease
progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 22-50 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Mario Sznol, MD
United States: Federal Government
|University of Texas - MD Anderson Cancer Center||Houston, Texas 77030-4009|
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|University of Minnesota Cancer Center||Minneapolis, Minnesota 55455|
|Sarah Cannon Cancer Center at Centennial Medical Center||Nashville, Tennessee 37203|